Xintela AB (OSTO:XINT) Cyclically Adjusted FCF per Share: kr-0.35 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:XINT Xintela AB OSTO:XINT
8 GF Score
Price kr0.19
! 2 Warning Signs
View Full Analysis

What is Xintela AB Cyclically Adjusted FCF per Share?

Xintela AB OSTO:XINT -1.81% 8 Cyclically Adjusted FCF per Share is kr-0.35 as of Mar. 2026. GuruFocus rates OSTO:XINT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Xintela AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.014. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-0.35 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-19), Xintela AB's current stock price is kr0.19. Xintela AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-0.35. Xintela AB's Cyclically Adjusted Price-to-FCF of today is .


Xintela AB  (OSTO:XINT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Xintela AB Cyclically Adjusted FCF per Share Related Terms


Xintela AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Xintela AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xintela AB Cyclically Adjusted FCF per Share Chart

Xintela AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.80 -0.37

Xintela AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 -0.40 -0.39 -0.37 -0.35

OSTO:XINT vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Xintela AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xintela AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xintela AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Xintela AB's Cyclically Adjusted Price-to-FCF falls into.


OSTO:XINT
8GF Score
Xintela AB OSTO:XINT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xintela AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xintela AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.014/133.5600*133.5600
=-0.014

Current CPI (Mar. 2026) = 133.5600.

Xintela AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.105 101.019 -0.139
201609 -0.077 101.138 -0.102
201612 -0.078 102.022 -0.102
201703 -0.134 102.022 -0.175
201706 -0.097 102.752 -0.126
201709 -0.117 103.279 -0.151
201712 0.012 103.793 0.015
201803 -0.170 103.962 -0.218
201806 -0.078 104.875 -0.099
201809 -0.096 105.679 -0.121
201812 -0.371 105.912 -0.468
201903 -0.145 105.886 -0.183
201906 -0.137 106.742 -0.171
201909 -0.127 107.214 -0.158
201912 -0.055 107.766 -0.068
202003 -0.001 106.563 -0.001
202006 -0.143 107.498 -0.178
202009 -0.207 107.635 -0.257
202012 0.074 108.296 0.091
202103 -0.176 108.360 -0.217
202106 -0.220 108.928 -0.270
202109 0.039 110.338 0.047
202112 0.047 112.486 0.056
202203 -0.059 114.825 -0.069
202206 -0.016 118.384 -0.018
202209 -0.144 122.296 -0.157
202212 -0.055 126.365 -0.058
202303 -0.018 127.042 -0.019
202306 -0.007 129.407 -0.007
202309 -0.083 130.224 -0.085
202312 -0.020 131.912 -0.020
202403 0.005 132.205 0.005
202406 -0.021 132.716 -0.021
202409 0.002 132.304 0.002
202412 -0.027 132.987 -0.027
202503 -0.014 132.825 -0.014
202506 -0.010 133.699 -0.010
202509 -0.010 133.480 -0.010
202512 -0.022 133.390 -0.022
202603 -0.014 133.560 -0.014

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-0.35 mean?
Xintela AB (OSTO:XINT) has a Cyclically Adjusted FCF per Share of kr-0.35 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xintela AB and its competitors.
Is Xintela AB's Cyclically Adjusted FCF per Share too high?
Xintela AB's current Cyclically Adjusted FCF per Share is kr-0.35. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Xintela AB's Cyclically Adjusted FCF per Share of kr-0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xintela AB and its competitors. Xintela AB's current Cyclically Adjusted FCF per Share is kr-0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (OSTO:XINT) has a current Cyclically Adjusted FCF per Share of kr-0.35. The current Cyclically Adjusted FCF per Share is kr-0.35. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Xintela AB (OSTO:XINT), the current Cyclically Adjusted FCF per Share is kr-0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xintela AB Business Description

Other Exchanges 1XT:Germany
Address Medicon Village, Lund, SWE, 223 81
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score

Get the complete analysis for OSTO:XINT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.19
Price